Abdel-Ghanie Abu-Samra, MD
Pulmonary Disease · Wichita, KSNPI 1134383177
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Inari Medical, Inc. at 32.3% of the total. Reporting peaked in 2024 at $19,022 and has fallen 89.2% since, to $2,055 in 2025. Among pulmonary disease clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $458.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$19K
- Boehringer Ingelheim$16K
- Intuitive Surgical$10K
- Vapotherm Inc$10K
- AstraZeneca$996
- Livanova USA, Inc.$719
- plus $2K from 14 others
What the payments were for
- Consulting fees$10,41917%
- Speaking & faculty fees$30,28550%
- Travel & lodging$9,16315%
- Food & beverage$6,44311%
- Education$3,7906%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 27 | $19,411 |
| Boehringer Ingelheim | 18 | $15,910 |
| Intuitive Surgical | 41 | $10,464 |
| Vapotherm Inc | 11 | $10,448 |
| AstraZeneca(2 entities) | 8 | $996 |
| Livanova USA, Inc. | 4 | $719 |
| Pulmonx Corporation | 3 | $386 |
| Jazz Pharmaceuticals Inc. | 2 | $275 |
| Sanofi | 2 | $230 |
| GSK | 2 | $225 |
| Abiomed | 2 | $214 |
| Veran Medical Technologies, Inc. | 2 | $178 |
| Merck | 1 | $125 |
| Stryker | 1 | $122 |
| Vifor Pharma, Inc. | 1 | $106 |
| Actelion Pharmaceuticals US, Inc. | 1 | $96 |
| United Therapeutics Corporation | 1 | $69 |
| Olympus America Inc. | 1 | $69 |
| CSL Behring | 2 | $40 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$19,081
- CT THROMBECTOMY SYSTEM KIT$19,081
- VAPOTHERM$10,419
- Da Vinci Surgical System$6,585
- ION$3,000
- TandemLife$660
- CHARTIS CATHETER$386
- ZEPHYR DELIVERY CATHETER$386
- ZEPHYR ENDOBRONCHIAL VALVE$386
- PULMONX CHARTIS TABLET CONSOLE$386
- DUPIXENT$355
- ZEPZELCA$275
- IMFINZI$249
- NUCALA$125
- TEZSPIRE$125
- TAGRISSO$125
- FASENRA$125
- WINREVAIR$125
- CLOTTRIEVER BOLD CATHETER$122
- AIRSUPRA$121
How this compares
$60,099 in reported general payments places this provider in the 95th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 54 | $678,611 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 807 | $586,262 |
| OfevNintedanib Esylate | 41 | $560,197 |
| Dupixent PenDupilumab | 104 | $452,430 |
| UptraviSelexipag | 15 | $423,287 |
| XolairOmalizumab | 118 | $349,525 |
| Fasenra PenBenralizumab | 36 | $207,959 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 248 | $192,276 |
| AdempasRiociguat | 13 | $183,072 |
| Breo ElliptaFluticasone/Vilanterol | 371 | $172,176 |
| NucalaMepolizumab | 32 | $123,258 |
| Orenitram ErTreprostinil Diolamine | 16 | $78,271 |
| Spiriva RespimatTiotropium Bromide | 97 | $61,549 |
| Incruse ElliptaUmeclidinium Bromide | 88 | $44,256 |
| Advair HfaFluticasone Propion/Salmeterol | 69 | $34,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $96 | $1,101,89869 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Arnuity Ellipta | $225 | $955,5311,404 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $15,910 | $652,150193 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $996 | $222,114342 claims |
| MerckDulera | $125 | $12,03025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Wichita
- Victor SalloumWichita$14K
- Ibrahim RaphaelWichita$13K
- Nader EldikaWichita$9K
- Dennis Oyieng'oWichita$9K
- Mark WencelWichita$9K
- John FlesherWichita$7K
- Youssef YammineWichita$6K
- Raid Abu-AwwadWichita$6K
- Maged El-ZeinWichita$4K
- Son TruongWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.